year 16, Issue 1 (January - February 2022)
Iran J Med Microbiol 2022, 16(1): 1-16 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Haji Ali Babaei R, Shapoori R, Beig M. Evaluation of Alginate-Exotoxin A Conjugated Vaccine Immunogenicity Against Pseudomonas aeruginosa Infection in Mouse Model. Iran J Med Microbiol 2022; 16 (1) :1-16
URL: http://ijmm.ir/article-1-1425-en.html
URL: http://ijmm.ir/article-1-1425-en.html
1- Department of Microbiology, Zanjan Branch, Islamic Azad University, Zanjan, Iran
2- Biologic Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran , drreza1357@gmail.com
3- Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran
2- Biologic Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran , drreza1357@gmail.com
3- Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran
Abstract: (1749 Views)
Background and Objective: Pseudomonas aeruginosa is an opportunistic pathogen, and alginate is its most important factor in pathogenicity. The objective of the study is the immunogenicity evaluation of P. Pseudomonas aeruginosa alginate conjugated to exotoxin A as a vaccine candidate in mice.
Materials and Methods: The mucoid strain of Pseudomonas aeruginosa 6494 was used to prepare alginate, and the separation of exotoxin A was done with the standard strain of PAO1. Alginate was extracted by means of sedimentation with cold ethanol, dialysis, enzymatic digestion and chromatography. To improve immunogenicity, purified antigen was coupled to exotoxin A with ADH as a spacer and EDAC as a linker. Based on confirmation tests, the resulting conjugate was devoid of specific toxicity and pyrogenic effect. Four groups of BALB/c female mice (each group was included 15 mice) were selected in the next step. The first group with the ALG, the second group with the D-ALG-ETA, and the third one with the ETA were vaccinated. The fourth group (control group) was vaccinated with normal saline. Vaccination was performed in three injectable doses with two-week intervals. Subsequently, serum samples were collected, and antibody responses were measured by the ELISA method for total IgG, IgG1, IgG2a, IgG2b, IgG3.
Results: After the second and third doses with ALG-ETA showed a significant increase in antibody titer against ALG-ETA in comparison with pure ALG. The titers of IgG2a, IgG2b, IgG, IgG1, IgG3 antibodies that produced against alginate increased in the third injection compared to the first conjugate injection, which was 2.9, 3, 5.2, 10, and 9.2, respectively.
Conclusion: These results show that ALG from Pseudomonas aeruginosa increases anti-alginate antibodies in conjugate form with exotoxin A and can be considered an appropriate, effective adjuvant.
Type of Study: Original Research Article |
Subject:
Medical Bacteriology
Received: 2021/08/11 | Accepted: 2021/12/30 | ePublished: 2022/01/20
Received: 2021/08/11 | Accepted: 2021/12/30 | ePublished: 2022/01/20
References
1. Luscher A, Simonin J, Falconnet L, Valot B, Hocquet D, Chanson M, et al. Combined Bacteriophage and Antibiotic Treatment Prevents Pseudomonas aeruginosa Infection of Wild Type and cftr- Epithelial Cells. Front Microbiol. 2020;11:1947. [DOI:10.3389/fmicb.2020.01947] [PMID] [PMCID]
2. Ghods Zadeh M, Moradi Bidhendi S, Ashrafi F. Comparative Study of Garlic Extract Effect on the Expression of Genes Involved in Quorum Sensing in Pseudomonas aeruginosa and the Antibiotic Tobramycin. Iran J Med Microbiol. 2021;15(1):107-20. [DOI:10.30699/ijmm.15.1.107]
3. Hoseinpoor Mohammad Abadi Z, Mokhtari A, Ebrahimi Kahrizsangi A. Evaluation of the Effect of a Number of Commercial Disinfectants on Pseudomonas aeruginosa Isolates Obtained from Human Infection Cases. Iran J Med Microbiol. 2020;14(2):138-53. [DOI:10.30699/ijmm.14.2.138]
4. Beig M, Arabestani MR. Investigation of MexAB-OprM efflux pump gene expression in clinical isolates of pseudomonas aeruginosa isolated from Intensive Care Unit. Iran J Med Microbiol. 2019;13(2):142-50. [DOI:10.30699/ijmm.13.2.142]
5. Law N, Logan C, Yung G, Furr CL, Lehman SM, Morales S, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665-8. [DOI:10.1007/s15010-019-01319-0] [PMID]
6. Howlin RP, Cathie K, Hall-Stoodley L, Cornelius V, Duignan C, Allan RN, et al. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Mol Ther. 2017;25(9):2104-16. [DOI:10.1016/j.ymthe.2017.06.021] [PMID] [PMCID]
7. Dehghan D, Fasihi-Ramandi M, Taheri R. Investigation of Synergism of Silver Nanoparticle and Erythromycin Inhibition and Detection of Exotoxin-A Gene in Pseudomonas aeruginosa Isolated from Burn Wounds Secretion. Iran J Med Microbiol. 2020;14(4):379-87. [DOI:10.30699/ijmm.14.4.379]
8. Pournajaf A, Razavi S, Irajian G, Ardebili A, Erfani Y, Solgi S, et al. Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates. Infez Med. 2018;26(3):226-36.
9. Safari Zanjani L, Shapouri R, Dezfulian M, Mahdavi M, Shafiee Ardestani M. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model. World J Microbiol Biotechnol. 2019;35(6):94. [DOI:10.1007/s11274-019-2669-y] [PMID]
10. Dieffenbach M, Pastan I. Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy. Biomolecules. 2020;10(7):979. [DOI:10.3390/biom10070979] [PMID] [PMCID]
11. Mokhtari K, Amini K. Identification of virulence genes in Pseudomonas aeruginosa isolated from human and animal samples by multiplex-PCR and their antibiotic resistance pattern. Iran J Med Microbiol. 2019;13(4):294-301. [DOI:10.30699/ijmm.13.4.294]
12. Safari zanjani L, Shapoury R, Dezfulian M, Mahdavi M, Shafieeardestani M. Preparation of PLGA (poly lactic-co-glycolic acid) nanoparticles Containing Pseudomonas aeruginosa Alginate, LPS and Exotoxin A as a Nano-vaccine. Biol J Microorganism. 2018;7(26):11-27.
13. Farjah A, Owlia P, Siadat SD, Mousavi SF, Ardestani MS, Mohammadpour HK. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa. APMIS. 2015;123(2):175-83. [DOI:10.1111/apm.12337] [PMID]
14. Kashef N, Behzadian-Nejad Q, Najar-Peerayen S, Mousavi-Hosseini K, Moazeni M, Rezvan H, et al. Preliminary investigation on the isolation of alginate produced by mucoid Pseudomonas aeruginosa. Ann microbiol. 2005;55(4):279-82.
15. Abdi-Ali A, Khani-Juy Abad F, Gharavi S. Antibiofilm activities of certain biocides in Pseudomonas aeruginosa. Iran J Microbiol. 2009;1(4):23-7.
16. Canh Do G, Lin F-y, Thiem Vu D, Trach Dang D, Trong Nguyen D, Mao Nguyen D, et al. Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese Children. Infect Immun. 2004;72(11):6586-8. [DOI:10.1128/IAI.72.11.6586-6588.2004] [PMID] [PMCID]
17. Faezi S, Bahrmand AR, Mahdavi M, Siadat SD, Sardari S, Nikokar I, et al. Preparation of Pseudomonas aeruginosa alginate-flagellin immunoconjugate. Biologicals. 2017;47:11-7. [DOI:10.1016/j.biologicals.2017.04.001] [PMID]
18. Kluger MJ, Vaughn LK. Fever and survival in rabbits infected with Pasteurella multocida. J Physiol. 1978;282(1):243-51. [DOI:10.1113/jphysiol.1978.sp012460] [PMID] [PMCID]
19. Nieman DC. Exercise immunology: practical applications. Int J Sports Med. 1997;18 Suppl 1(S1):S91-100. [DOI:10.1055/s-2007-972705] [PMID]
20. Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun. 2003;71(7):3875-84. [DOI:10.1128/IAI.71.7.3875-3884.2003] [PMID] [PMCID]
21. Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The Efficacy of a Salmonella typhi Vi Conjugate Vaccine in Two-to-Five-Year-Old Children. N Engl J Med. 2001;344(17):1263-9. [DOI:10.1056/NEJM200104263441701] [PMID]
22. Abu-Baker NF, Masoud H. Synthesis, Characterization, and Immunological Properties of LPS-Based Vaccines Composed of O-Polysaccharides Conjugated with Recombinant Exoprotein A from Pseudomonas aeruginosa. J Adv Microbiol. 2016;6(4):332-42. [DOI:10.4236/aim.2016.64032]
23. Tanomand A, Najar Peerayeh S, Farajnia S, Majidi J. Protective Properties of Nontoxic Recombinant Exotoxin A (Domain I-II) Against Pseudomonas aeruginosa Infection. Iran J Biotechnol. 2013;11(3):193-98. [DOI:10.5812/ijb.10149]
24. Cryz SJ, Lang A, Rüdeberg A, Wedgwood J, Que JU, Fürer E, et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst Mitt. 1997(98):345-9.
25. Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, Moazzeni M, Djavid GE. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J Med Microbiol. 2006;55(10):1441-6. [DOI:10.1099/jmm.0.46696-0] [PMID]
26. Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB. Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection. Pediatr Infect Dis J 2004;23(6). [DOI:10.1097/01.inf.0000129688.50588.ac] [PMID]
27. Burns DL, Kossaczka Z, Lin Feng-Ying C, Ho Vô A, Thuy Nguyen Thi T, Bay Phan V, et al. Safety and Immunogenicity of Vi Conjugate Vaccines for Typhoid Fever in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam. Infect Immun. 1999;67(11):5806-10. [DOI:10.1128/IAI.67.11.5806-5810.1999] [PMID]
28. Lanh MN, Van Bay P, Ho VA, Thanh TC, Lin FYC, Bryla DA, et al. Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children. N Eng J Med. 2003;349(14):1390-1. [DOI:10.1056/NEJM200310023491423] [PMID]
29. Afshari H, Maleki M, Hakimian M, Tanha RA, Salouti M. Immunogenicity evaluating of the SLNs-alginate conjugate against Pseudomonas aeruginosa. J Immun Methods. 2021;488:112938. [DOI:10.1016/j.jim.2020.112938] [PMID]
30. Najafzadeh F, Shapouri R, Rahnema M, Rokhsartalab Azar S, Kianmehr A. Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity. Jundishapur J Microbiol. 2015;8(6):e17712-e. [DOI:10.5812/jjm.8(5)2015.17712]
31. Winstanley C, Coulson MA, Wepner B, Morgan JAW, Hart CA. Flagellin gene and protein variation amongst clinical isolates of Pseudomonas aeruginosa. Microbiol. 1996;142(8):2145-51. [DOI:10.1099/13500872-142-8-2145] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Iranian Journal of Medical Microbiology by Farname is licensed under CC BY-NC 4.0
